You just read:

Enobia Announces Completion of Enrollment in Third Phase II Hypophosphatasia Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy

News provided by

Enobia Pharma Inc.

Feb 24, 2011, 11:52 ET